We continue our look back at the heritage of the Beckley Foundation’s ground-breaking research programmes and the potential for Beckley Psytech, which leverages the Foundation’s knowledge and research capabilities through a close strategic partne... Read More
Beckley Psytech’s CEO Cosmo Feilding Mellen comments on 5-MeO-DMT’s potential to rival psilocybin as a cost-effective psychedelic treatment for depression and addiction.
Exclusive news article on the Beckley Psytech’s partnership with Fluence to develop a psychedelic-assisted psychotherapy training programme for 5-MeO-DMT, featuring quotes from CEO Cosmo Feilding Mellen and Chief Medical Advisor Dr Fiona Dunbar.
News article on the appointment of Adam George as Beckley Psytech’s new Independent Director, bringing nearly two decades of experience in the pharmaceuticals industry to the Board.
Q&A with Beckley Psytech CEO Cosmo Feilding Mellen
Our latest series looks at the heritage of the Beckley Foundation’s groundbreaking research programmes and the potential for Beckley Psytech, which leverages the Foundation’s knowledge and research capabilities through a close strategic partnersh... Read More
Article featuring Beckley Psytech among the European companies set to dominate the psychedelic medicine market, with comments from CEO Cosmo Feilding-Mellen.